Abstract:Immunotherapy has emerged as a hot topic in the treatment of non-small cell lung cancer (NSCLC) with remarkable success. Compared to chemotherapy patients, the 5-year survival rate for immunotherapy patients is 3-fold higher, approximately 4%–5% versus 15%–16%, respectively. Immunotherapies include chimeric antigen receptor T-cell (CAR-T) therapy, tumor vaccines, immune checkpoint inhibitors, and so forth. Among them, immune checkpoint inhibitors are in the spotlight. Common immune checkpoint inhibitors (ICIs) currently in clinical use include programmed death receptor-1(PD-1)/programmed death ligand-1(PD-L1) and cytotoxic T lymphocyte-associated antigen 4(CTLA-4). This article focuses on monotherapy and combination therapy of CTLA-4 and PD-1/PD-L1 immune checkpoint inhibitors. In particular, the combination therapy of ICIs includes the combination of ICIs and chemotherapy, the combination therapy of dual ICIs, the combination of ICIs and anti-angiogenic drugs, the combination of ICIs and radiotherapy, and the combination of ICIs inhibitors and tumor vaccines and so forth. This article focuses on the combination therapy of ICIs with chemotherapy, the combination therapy of dual ICIs, and the combination therapy of ICIs with anti-angiogenic drugs. The efficacy and safety of ICIs as single agents in NSCLC have been demonstrated in many trials. However, ICIs plus chemotherapy regimens offer significant advantages in the treatment of NSCLC with little to no dramatic increase in toxicity, while combined dual ICIs significantly reduce the adverse effects (AEs) of chemotherapy. ICIs plus anti-angiogenic agents regimen improves anti-tumor activity and safety and is expected to be the new paradigm for the treatment of advanced NSCLC. Despite some limitations, these agents have achieved better overall survival rates. In this article, we review the current status and progress of research on ICIs in NSCLC in recent years, aiming to better guide the individualized treatment of NSCLC patients.

Treatment of non-small cell lung cancer comes to the age of immunotherapy

Application of Immune Checkpoint Inhibitors in EGFR-mutant Non-Small-cell Lung Cancer: from Bed to Bench

Medical treatment of non-small cell lung cancer:An update

Current status of immunotherapy for non-small cell lung cancer

First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects

Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges

Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy

A retrospective study of second-line chemotherapy combined with immunotherapy in advanced non-small cell lung cancer

Combination Strategies of Immunotherapy in Non-Small Cell Lung Cancer: Facts and Challenges

Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application

Immunotherapy in Lung Cancer: A New Age in Cancer Treatment

Current status of clinical trial research and application of immune checkpoint inhibitors for non-small cell lung cancer

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

New promises and challenges in the treatment of advanced non-small-cell lung cancer

Research Advances in Mechanism of Antiangiogenic Therapy Combined with Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer

[Combination therapy based on PD-1/PD-L1 blocking in the treatment of non-small cell lung cancer]

Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates

Novel Immunotherapeutics for the Treatment of Non-Small Cell Lung Cancer (NSCLC) Resistant to PD-1/PD-L1 Inhibitors

Neoadjuvant immunotherapy for non–small cell lung cancer: State of the art

Current therapy of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)